Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

Receptor editing

From Wikipedia, the free encyclopedia

Receptor editing is a process that occurs during the maturation of B cells, which are part of the adaptive immune system. This process forms part of central tolerance to attempt to change the specificity of the antigen receptor of self reactive immature B-cells, in order to rescue them from programmed cell death, called apoptosis.[1] It is thought that 20-50% of all peripheral naive B cells have undergone receptor editing making it the most common method of removing self reactive B cells.[2]

During maturation in the bone marrow, B cells are tested for interaction with self antigens, which is called negative selection. If the maturing B cells strongly interact with these self antigens, they undergo death by apoptosis. Negative selection is important to avoid the production of B cells that could cause autoimmune diseases. They can avoid apoptosis by modifying the sequence of light chain V and J genes (components of the antigen receptor) so that they have a different specificity and may not recognize self-antigens anymore. This process of changing the specificity of the immature B cell receptor is called receptor editing.

References

[edit]
  1. Meffre, E; Wardemann, H (2008). "B-cell tolerance checkpoints in health and autoimmunity". Current Opinion in Immunology. 20 (6): 632–638. doi:10.1016/j.coi.2008.09.001. PMID 18848883.
  2. Halverson R, Torres RM, Pelanda R (2004). "Receptor editing is the main mechanism of B cell tolerance toward membrane antigens". Nature Immunology. 5 (6): 645–650. doi:10.1038/ni1076. PMID 15156139. S2CID 20869465.
    3. Kleinfield R, Hardy RR, Tarlinton, D (1986). 'Recombination between an expressed immunoglobulin heavy-chain gene and a germline variable gene segment in a          
Ly1+ B-cell lymphoma'. Nature 322 (6082): 843-6.